HeLa In Vitro Representational Difference Analysis (RDA) Assay
CAT#: ITS-1022-YF5229
Target Cell Organism: Human
Target Cell Name: HeLa
Assay Type: Genome Alteration Assays
Assay Overview
This assay is to provide HeLa-based In Vitro Representational Difference Analysis (RDA) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.
Target Cell Name
HeLa
Target Cell Organism
Human
Target Cell Background
In 1952, HeLa cells became the first human cell line that could grow and divide endlessly in a laboratory, leading scientists to label these cells "immortal". The immortality of HeLa cells contributed to their adoption across the world as the human cell line of choice for biomedical research.
Related Diseases
Cervical Cancer
Research Area
Oncology
Assay Name
In Vitro Representational Difference Analysis (RDA) Assay
Short Description
HeLa-cell based In Vitro Representational Difference Analysis (RDA) Assay
Assay Description
This technique can detect sequence differences of two different DNA segments. In representational difference analysis, genomes to be compared are digested by specific restriction enzymes and ligated to specific oligonucleotide linkers, providing two different representations of the two genomes to be generated by PCR with primers specific for oligonucleotide linkers. Following the generation of amplicons, oligonucleotide linkers are removed and a new linker is attached only to test amplicons. These amplicons (tester) are then mixed with driver amplicons, which lack linkers. Amplification only occurs with DNA fragments specific to the tester (with primers specific for linkers).
Assay Type
Genome Alteration Assays
Assay Type Details
Aberrant or somatic mutations are more commonly found in the DNA of cancer cells compared to normal cells. There is an equilibrium that exists between DNA damage and repair in normal cells. However, in cancer cells these events are disturbed, resulting in mutations and genomic instability. Genomic instability in cancer cells causes chromosomal aberrations, microsatellite instability, aneuploidy and uncontrolled gene amplifications and genetic instability in cancer cells are mainly due to point mutations or chromosomal aberrations such as insertions, deletions and translocation, resulting in mutated proteins.